The Valley Desk

NCT02997202 · Interventional trial

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Overall registry status Completed

Phase 3

Conditions Acute Myeloid Leukemia

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov